Back to search

National and Kapodistrian University of Athens

Μη επεμβατικός προγεννητικός έλεγχος συστήματος RhD του εμβρύου απο περιφερικό αίμα της εγκύου

Abstract

dc:description

Rhesus D (RhD) system incompatibility between a pregnant woman and her fetus can result in maternal alloimmunization and hemolytic disease of the fetus /newborn (HDFN) in subsequent pregnancies. Routine antenatal anti-D administration to all RhD-negative pregnant women significantly prevents the occurrence of HDFN. Based on this prophylactic approach, however, anti-D is unnecessarily given to approximately 40% of RhD-negative women carrying RhD-negative fetuses, thus wasting time, money and valuable anti-D. In addition, since anti-D is produced from pooled plasma obtained from immunized RhD-negative donors its use is related to risks associated with administration of human blood products. Prenatal determination of fetal RhD status can be performed using fetal genetic material obtained through amniocentesis or CVS sampling. These invasive procedures, however, carry an approximately 0.5-1% risk of miscarriage and most importantly, they may lead to immunization due to feto-maternal hemorrhage. The development of safer methods using cell-free fetal DNA (cffDNA) for obtaining fetal genetic material for RHD prenatal detection, offers significant potential for the management of RhD-negative pregnant women. The aim of the present study was to design, optimize and validate protocols for reliable and accurate non-invasive prenatal determination of the fetal RhD status, using cffDNA isolated from RhD-negative pregnant women plasma. Blood samples from 132 RhD-negative pregnant women (7-24 weeks of gestation) were analyzed. Protocols were validated using 84 samples. Following that, the approved protocol was applied for routine clinical use in 48 samples. In the 1st part of the study, fetal RhD status was determined using RTQ-PCR for RHD exon 7 sequence detection. SRY gene sequences were analyzed in a separate reaction in order to confirm the presence of cffDNA in the sample tested. Diagnosis was accurate in 37/40 cases (92.5%). 30/32 RhD-positive and 7/8 RhD-negative fetuses were successfully diagnosed (93.8% sensitivity and 87.5% specificity). In the 2nd part of the study, a protocol for non-invasive prenatal diagnosis of fetal RhD status was designed which could verify the presence of cffDNA in maternal plasma, independently of fetal gender or parental polymorphisms. The protocol involved enzyme digestion of maternal plasma cell-free DNA (cfDNA), using a methylation specific endonuclease (AciI), followed by a multiplex PCR that allowed simultaneous amplification of exons 7 and 10 of the RHD gene (fetal RhD status determination), SRY to confirm the presence of cffDNA in pregnancies with male fetus, RASSF1A to confirm the presence of cffDNA and ACTB (assessment of digestion efficiency) sequences. It is known that RASSF1A sequences are hypermethylated in placenta but hypomethylated in maternal blood cells. In this case, methylation-sensitive endonuclase digests maternal hypomethylated RASSF1A sequences, leaving intact for amplification those of placental origin. During protocol validation, in 1/84 cases the presence of an RHD variant allele was suspected and the sample was excluded from the study. Fetal RhD status determination was accurate in 82/83 cases (98.8%) with 1 false-positive result. 53/53 RhD-positive and 29/30 RhD-negative fetuses were successfully diagnosed giving 100% sensitivity and 96.7% specificity. The multiplex PCR protocol was applied to 48 cfDNA samples for the clinical management of the pregnancy. All fetuses were successfully diagnosed (37 RhD-positive and 11 RhD-negative). This is the first report in the literature of a multiplex PCR based protocol for non-invasive prenatal diagnosis of fetal RhD status that can simultaneously verify the presence of cffDNA in the sample tested, thus avoiding inconclusive and false-negative results. Results indicate that the described protocol provides a good basis for routine examination of fetal RhD status by a non-invasive, risk-free method for the management of immunized RhD-negative women as well as for screening for fetal RhD typing in non-immunized, RhD-negative pregnant women. The technique is rapid, robust and in concordance with the degree of accuracy needed for non invasive fetal RHD genotyping. Its efficiency, sensitivity and specificity are similar to that obtained when RTQ-PCR is used. Since the proposed protocol requires no specially designed and expensive equipment and reagents, it is easily applicable in most molecular diagnostic laboratories.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2012

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tounta, Georgia
  • Τούντα, Γεωργία

Subjects

dc:subject × 15

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/32885

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tounta, Georgia; Τούντα, Γεωργία. Μη επεμβατικός προγεννητικός έλεγχος συστήματος RhD του εμβρύου απο περιφερικό αίμα της εγκύου. National and Kapodistrian University of Athens, 2012. http://hdl.handle.net/10442/hedi/32885